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Dose-effect and pharmacokinetics of estrogens given to correct bleeding
time in uremia. Conjugated estrogens have a significant and long-lasting
effect in shortening bleeding time in patients with end-stage renal
disease. The studies so far available indicate that repeated estrogen
administrations are necessary to short bleeding time in uremia in a dose
range of 95 to 325 mg. With the present study we wanted to establish
whether single or repeated doses are required to induce a significant
shortening of bleeding time in uremia, and the minimum cumulative
dose of conjugated estrogens necessary to control bleeding time for a
prolonged period of time, and to check whether the prolonged effect of
estrogens on bleeding time in uremia is due to an accumulation of the
drug or its metabolites in the blood. Fifteen uremics on chronic
hemodialysis were studied, A pilot study carried out in five uremic
patients indicated that single or repeated estrogen infusions of 0.3 mgI
kg did not significantly influence bleeding time values. Therefore the
subsequent studies have been carried out using daily infusion of 0.6 mgI
kg. A single estrogen infusion of 0.6 mg/kg shortened bleeding time in
all patients. The effect was transient and bleeding time returned to
pre-infusion values within 72 hours. A 50% decrease of bleeding time or
a shortening of bleeding time more than 30 to 15 minutes or less was
obtained in all patients with four or five infusions (0.6 mg/kg) spaced 24
hours apart. The effect lasted for 14 days. At day 25 from the last
infusion all the patients had bleeding time values comparable with the
pre-infusion ones. Pharmacokinetic parameters of both estrone sulfate
and equilin sulfate, the major components of the estrogen mixture we
used, were comparable in both controls and uremics and can be
described assuming a two compartmental model. After repeated admin-
istrations of conjugated estrogens no accumulation of estrone sulfate
and equilin sulfate or their metabolites was detectable in blood in both
uremics and controls.
Bleeding in chronic renal failure has been the subject of
intensive investigation in the recent years. The most effective
therapeutic measures to date are red cell transfusions [1, 2],
cryoprecipitate [3], and desmopressin (l-deamino-8-D-arginine
vasopressin) [4—6]. However, red cell transfusions and cryopre-
cipitate carry the risk of transmitting blood-associate infections.
Moreover, both cryoprecipitate and desmopressin have a short
duration of effect [3, 4]. Recently it has been found that
conjugated estrogens shorten the prolonged bleeding time of
uremics and stop severe hemorrhages [7, 8]. Estrogens, by
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virtue of their long duration of action, are particularly effective
when long-lasting "hemostatic" correction is required.
Studies published to date have employed a wide range of
estrogen dosages (95 to 325 mg) administered in a variety of
different regimens. Whether repeated administrations are really
necessary to obtain a long lasting effect on bleeding time is not
known, nor information is available on the minimum dose of
conjugated estrogens actually needed to correct the hemostatic
defect of uremia. Given the potentially major side effects of
estrogens [9, 10] the area is worth investigating. Moreover
studies on estrogen pharmacokinetics in uremics in relationship
to the estrogen effect on the bleeding time have not been done
so far.
The aims of the present study were: 1) to investigate whether
single or repeated doses of estrogens are required to induce a
significant shortening of bleeding time in uremia; 2) to establish
the minimum effective cumulative dose necessary to control
bleeding time for a prolonged period of time; and 3) to check
whether the reported long-lasting effect of estrogens in short-
ening bleeding time in uremia is due to an accumulation of the
drug or of its metabolites in the blood.
Methods
Subjects
Fifteen patients with chronic renal failure (CRF) and three
control subjects participated in the study. CRF patients (10 men
and 5 women; median age, 52 years; range, 32 to 65) with
diagnosis of chronic glomerulonephritis (N = 8), chronic pyelo-
nephritis (N = 5) and interstitial nephritis (N = 2), were being
treated in our renal unit and were admitted to the study on the
basis of the concomitant presence of chronic renal failure with
anuria and prolonged bleeding time (longer than 15 minutes).
All the patients had normal results on coagulation screening
tests (fibrinogen, prothrombin time, activated partial thrombo-
plastin time, and thrombin time) before and after the study.
During the study, no technical changes were done in dialytic
treatment (that is, changing heparin dosing) and no significant
changes were observed in hematocrit and blood urea nitrogen
values for each patient (data not shown). The mean platelet
count (± SD) was 275 61 x l0 per cubic milliliter (range 190
to 370 x l0). None of the patients received transfusions or
blood derivatives during the three months preceding the study
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or during the study. None of the patients had taken aspirin or
other drugs known to affect platelet function for at least 20 days
before the study. All patients were requiring therapeutic hemo-
dialysis three times a week (12 hours per square meter parallel
flow kidney with cuprophan membrane). All patients were
aware of the nature and purposes of the study and all gave
informed consent in accordance with the Declaration of Hel-
sinki.
Healthy subjects (2 men and 1 woman; median age, 46 years;
range 34 to 61) had not received drugs during the three months
preceding the study or during the study. All were aware of the
nature and purposes of the study and all gave informed consent
in accordance with the Declaration of Helsinki.
Design of the study
Since the first study carried out in five uremic patients
indicated that single or repeated estrogen infusions of 0.3 mg/kg
did not significantly influence bleeding time values, all the
subsequent studies were carried out using daily infusion of 0.6
mg/kg. Patients (N = 10) received cycles of conjugated estro-
gens infusion (Emopremarin, Ayerst Laboratories, New York,
New York, USA) followed by a period of observation. The goal
of estrogen therapy was to reduce the bleeding time to at least
50% of the baseline value, or if more than 30 minutes, to a value
of 15 minutes or less. The experimental design was as follows:
the first infusion was given 24 hours after dialysis and a baseline
bleeding time determination. Bleeding times were repeated at 6,
24, 48, 72, and 96 hours and seven days after infusion. If the
prescribed reduction in bleeding time was not achieved within
seven days, the cycle was repeated with infusions on two
consecutive days followed by five days of observation. If the
second cycle was also ineffective, then a third cycle with
infusion on three consecutive days was performed followed by
a fourth and fifth cycle when necessary. A wash-out period of at
least one month elapsed between each cycle of estrogen ther-
apy. Bleeding time was also monitored 14, 21, and 30 days after
the first infusion of the cycle.
Conjugated estrogens were added to 50 ml of physiologic
saline and infused over a period of 40 minutes in the arm
contralateral to the vascular access for hemodialysis. Blood
pressure and pulse rate were monitored during the infusion.
Pharmacokinetic parameters were determined by the noncom-
partmental pharmacokinetic method according to Gibaldi and
Perrier [111. Blood samples were taken immediately before
(time 0) and 40, 50 minutes, and 1, 2, 4, 6, 12, 24, 48, 72, and 96
hours after the first conjugated estrogen infusion plus 6 hours
after the start of each infusion.
Healthy subjects received five consecutive estrogen infusions
of 0.6 mg/kg each following the same schedule as for patients.
Bleeding time was determined before (time 0) and at 6, 24, 48,
72, 96 hours and seven days. Blood samples for pharmacoki-
netic parameters were taken immediately before (time 0) and
40, 50 minutes, and 1, 2, 4, 6, 12, 24, 48, 72 and 96 hours after
the first conjugated estrogen infusion and six hours after the
start of each infusion.
Blood collection
Venous blood samples (5 ml) were collected through a
19-gauge needle into heparinized syringes. Platelet poor plasma
was obtained after centrifugation (4000 x g for 20 mm) at room
temperature, was quick-frozen, and kept at —80°C until tested.
Bleeding time measurement
Template bleeding time was performed by the same investi-
gator with the Simplate II device (General Diagnostic, Milan,
Italy) on the antecubital surface of the forearm, under a counter
pressure of 40 mm Hg. The blood was blotted every 30 seconds
until no more appeared at the site of tranverse standard
incisions. The time of bleeding was recorded for a maximum of
30 minutes. Results were expressed as the average bleeding
time from the two incisions. The normal range with this method
in 10 healthy women and 10 healthy men was three to seven
minutes.
Pharmacokinetic assay
Plasma concentrations of estrone sulfate (E1S) and its major
metabolites, estrone (E1) and estradiol (E2), and of equilin
sulfate (EQS) and its major metabolite equilin (EQ), were
determined by high-performance liquid chromatography
(HPLC). Briefly: 1 ml of plasma was added to a centrifuge tube
containing 50 j.d of tetrabutylammonium hydrogen sulfate
(TBA), 2.5 m adjusted to pH 3.0 0.1 with NaOH, and was
vortexed for few seconds. Seven ml of chloroform were added
to each tube, and the samples were vortexed for 30 seconds.
After centrifugation, the organic layer was separated and evap-
orated to dryness. The residue was dissolved in 200 .d of mobile
phase and exactly 50 l was injected into the liquid chromato-
graph. Using a model 334 liquid chromatograph equipped with
a model 163 variable wavelength detector (Beckman Instru-
ments, Inc., Fullerton, California, USA) operating at 215 nm
and a reversed-phase column (Ultraspheretm, ODS, 5 m, 250
x 4.6 mm, Beckman), the samples were eluted in isocratic
conditions with a mobile phase of acetonitrile:methanol:TBA
(12.5 m adjusted to pH 3.0 0.1 with NaOH) at 30:30:40, and
at a 1.0 mllmin flow rate. The retention times of E1S, E1, E2,
EQS, EQ were 6.7, 9.4, 7.9, 6.1, and 8.8 minutes, respectively.
Internal calibration curves of E1S, E1, E2, EQS, EQ, were
prepared for each set of samples. Linearity was found over the
investigated concentration range. The detection limit was 10 ng/
ml for each compound.
Statistical analysis
The values for bleeding time were not normally distributed
and differences were compared by means of the Friedman test
[12].
Pharmacokinetic parameters were analyzed by one-way anal-
ysis of variance, using Duncan test for multiple comparisons
[13]. Results are expressed as means SD. P values less than
0.05 were considered significant.
Results
Bleeding time
A single estrogen infusion of 0.3 mg/kg did not influence
bleeding time (basal: 19.6 3.8 mm; 6 hr after: 18.1 3.1 mm;
24 hr after: 19.1 3.1 mm). Two infusions of 0.3 mg/kg (spaced
24 hr apart) did not affect bleeding times (data not shown).
Three repeated infusions of 0.3 mg/kg shortened bleeding times,
but values did not reach statistically significant differences
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1
2
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4
5
6
7
8
9
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4
4
5
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5
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5
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21 10
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25 11
25 10
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21 9
17 8
72 (p < 0.05) and 96 hours, and at day 7 (P < 0.01). Within 30
days bleeding times returned to basal values (Fig. 1D).
Table 1 shows that in patients number 1, 2 and 9, daily
infusion for four consecutive days prolonged the control of
bleeding time for 14 days, while the remaining seven patients
required five infusions to reach the same end point. Indeed,
when this latter group of patients received five infusions of 0.6
mg/kg, the bleeding times significantly shortened at 96 hours (P
<0.05) and at days 7 and 14 (P < 0.01). The bleeding time at
day 21 was shorter than basal but the difference was not
significant. All these patients had bleeding time values compa-
rable to basal ones at day 30 (Fig. 1E).
Figure IF shows that five consecutive estrogen infusions in
healthy subjects did not influence bleeding times.
Pharmacokinetics
Emopremarin is a mixture of conjugated equine estrogens
derived from urine of pregnant mares. In the preparation used
in this study the content in sodium estrone sulfate and sodium
equilin sulfate was determined by HPLC method, and ac-
counted for 59% and 29%, respectively.
Mean E1S and EQS plasma concentrations after the infusion
of 0.6 mg/kg of Emopremarin (equivalent to 0.354 mg/kg E1S
and 0.174 mg/kg EQS) over a period of 40 minutes showed a
biexponential decline in both patients (Fig. 2) and controls.
Initial plasma concentrations of E1S were higher than those of
EQS, but about one hour after administration plasma levels of
EQS exceeded those of E1S. Individual and mean values for the
noncompartmental pharmacokinetic parameters of E1S and
EQS are shown in Table 2. The elimination half-life of E1S(t112)
varied widely and was similar in patients and controls (1.87
1.05 and 2.58 0.80 hr, respectively). A large variability was
also found for total body clearance (CL), 0.273 0.181 in
patients and 0.132 0.048 1 hr . kg' in controls, and for
apparent volume of distribution (V), 0.614 0.347 in patients
and 0.480 0.208 1 kg in controls, but these parameters were
not statistically different. A similar variability in the pharmaco-
kinetic parameters was observed also for EQS. No statistically
significant differences were found in t112 between patients and
controls (2.79 1.05 and 2.79 0.80 hr, respectively); in all the
subjects but one (patient 8) t112 for EQS was longer than for
E1S. Total body clearance was 0.118 0.078 in patients and
0.086 0.040 1 hr kg in controls (NS). Apparent volume of
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Fig. 1. Panels A to U show the effect on bleeding time of single and
repeated doses of estrogens (0.6 mg/kg) in uremic patients. Panels E
and F show the effect on bleeding time of 5 infusions in 7 uremic
patients and 3 healthy controls, respectively. Arrows indicate estrogen
infusions (°P < 0.05 and * < 0.01 vs. basal value). Data are expressed
as means SD.
(basal: 18.4 2.7 mm; 24 hr: 17.7 2.1 mm; 48 hr: 16.7 2.3
mm; 72 hr: 16.3 2.5 mm; 96 hr: 17.1 2.4 mm; day 7: 18.0
2.1 mm). On the basis of these data, we performed the subse-
quent studies using estrogen infusions at a dose of 0.6 mg/kg.
A single estrogen infusion of 0.6 mg/kg did shorten the
bleeding time (Fig. 1A) in all patients. Bleeding time shortening
was not statistically significant at six hours after estrogen
infusion (second solid circle, Fig. 1A). At the two subsequent
measurements, 24 and 48 hours after estrogen infusion, bleed-
ing times were significantly shorter (P < 0.01) than basal values.
Within 72 to 96 hours, bleeding times returned to pre-infusion
values (Fig. 1A).
The time course of bleeding time observed after repeated
estrogen infusions is represented in Figure 1. After two infu-
sions of 0.6 mg/kg, bleeding times were significantly shortened
at 48 and 72 hours (P < 0.01). Five to seven days after the first
infusion bleeding times returned to pre-infusion values (Fig.
1B). After three infusions of 0.6 mg/kg a significant shortening
of bleeding times was observed at 48 (P < 0.05), 72 and 96 hours
(P < 0.01). Seven days after the first infusion bleeding times
returned to the pre-infusion values (Fig. 1C). After four infu-
sions of 0.6 mg/kg bleeding times were significantly shortened at
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Fig. 2. Semilogarithmic plot of plasma estrone sulfate () and equilin
sulfate (El) concentrations in uremic patients after 40-minute infusion of
0.6 mg/kg of conjugated estrogens. Data are expressed as means SD.
distribution was 0.421 0.246 in patients and 0.345 0.186 1
kg' in controls (NS).
Table 3 shows the E1 S and EQS plasma levels in patients and
controls measured six hours after each infusion. Trough levels
measured immediately before the second, third, fourth and fifth
infusion were always under the detection limit (<10 ng/ml) even
at the fifth day of infusion (data not shown). These findings
suggest that the administered drug did not accumulate in the
blood stream. E1, E2, the major metabolites of E1S, and EQ, the
major metabolite of EQS, were always under the detection limit
of the method (data not shown). No side effects were noted
during or after infusion. There were no significant changes in
blood pressure or pulse rate during the treatment.
Discussion
Our present results confirm that conjugated estrogens effec-
tively shorten the bleeding time in uremia. The potential clinical
relevance of this finding is based on two considerations. First a
prolonged bleeding time in uremia correlates with clinical
bleeding [14]. Second, in addition to shortening the bleeding
time, estrogens are effective in inducing cessation of bleeding
[8] and maintenance of a prolonged hemorrhage-free period in
patients with chronic renal failure and recurrent gastrointestinal
bleeding [71. Two previous studies, one uncontrolled [7] and
one controlled [8], have documented that estrogens effectively
reduce bleeding time in uremia and that the effect lasts for
several days. In these studies estrogens have been used in
repeated administrations, that is, four to twenty infusions
spaced 12 or 24 hours apart. The present study was primarily
designed to comparatively evaluate the effect of single or
repeated doses of estrogens in determining a long-lasting effect
on bleeding time in chronic renal failure patients. The data
indicate that a single dose of 0.6 mg/kg was effective in
shortening the bleeding time in all patients. However, the effect
of 0.6 mg/kg as a single administration was transient, reaching
its maximum 24 hours and ending 72 hours after the beginning
of the infusion in all patients. Two to three daily infusions of 0.6
mg/kg estrogen resulted in a consistent, more pronounced and
more prolonged shortening of the bleeding time (maximum
effect between 72 and 96 hours; return to pre-infusion values at
day 7). A long-lasting effect of estrogens on bleeding time was
only observed in the present study when four to five consecu-
tive administrations of 0.6 mg/kg were given at 24 hour inter-
vals. Actually in three out of ten patients the bleeding time was
controlled for 14 days with four infusions and in seven out often
was controlled for the same time with five infusions. Between
16 and 25 days after the last infusion the bleeding time returned
to pre-treatment levels in all patients. This study documented a
cumulative effect of repeated dosing of conjugated estrogens. It
would seem that if six doses were given, a longer effect may
have been obtained. This possibility has to be taken into
account when a "hemostatic" competence longer than 20 to 30
days is required in patients at particular risk of bleeding such as
those with subdural hematoma or who undergo major surgery
[151.
Studies in healthy subjects have shown that E1S has a
relatively short-half life (4 to 6 hr) [16]. Moreover, E1 S has been
identified in human urine as itself or converted to estradiol
glucuronide and estriol [16, 171. It is therefore conceivable that
in chronic renal failure patients with anuria estrogens or their
metabolites accumulate in uremic blood after repeated admin-
istrations, thus accounting for the prolonged effect on bleeding
time. The second purpose of the present study was to verify the
above-mentioned hypothesis examining estrogen pharmacoki-
netics in uremics as compared to normal subjects. Information
on E1S and EQS pharmacokinetic parameters in uremia are not
available in the published literature. Our present results indi-
cate that pharmacokinetic parameters of both E1S and EQS
were comparable in uremics and controls; plasma concentration
of both compounds can be described assuming a two-compart-
ment model. Ruder, Loriaux and Lipsett [16] found that E1S
pharmacokinetics after rapid i.v. injection could be described
assuming a one-compartment model. These authors' sampling
was not frequent enough during the first hour after estrogen
administration, thus the early distributive phase might have
been missed. This interpretation is supported by the work of
Longcope [17], who according to our present findings described
the time course of E1S after intravenous injection using a
two-compartment model. Our present data showed a t112 for
E15 slightly shorter than that previously reported [16, 17],
which explains the lack of accumulation of the drug into the
blood stream. Our data indicate that for EQS also accumulation
did not occur, even though this compound is cleared more
slowly from plasma than E1S. As far as E1S major metabolites,
E1 and E2, are concerned, failure to identify measurable levels
of these two compounds in chronic renal failure patients even
after repeated estrogen administrations indicates that the lack
of estrogen metabolite urinary excretion is not an explanation
for the long lasting effect on bleeding time. Since estrogens can
be converted to estriol and oxidated to nonestrogenic substance
[17] in the enterohepatic circulation, one has to assume that this
is the major estrogen degradation pathway in uremia.
That repeated administrations of estrogens are necessary in
our patients to obtain a long-lasting "hemostatic" effect is not
surprising taking into account that estrogens are considered to
act via a receptor mechanism and that the magnitude of the
response is a function of the degree of occupation of the
receptor [18, 19]. An interesting finding of the present study is
the dissociation between short plasma half-life of estrogens or
0 1 2 3 4 5 6
Viganô et a!: Pharmacokinetics of estrogens in uremia 857
Table 2. Pharmacokinetic findings of estrone sulfate (E1S) and equilin sulfate (EQS) after conjugated estrogens infusion
Bod Ahr t1,2hr CL1 hr kg V1 kg
kg E1S EQS E1S EQS E1S EQS E1S EQS
Patient
1 41 0.45 0.26 1.52 2.72 0.228 0.107 0.502 0.420
2 65 0.85 0.47 0.82 1.48 0.267 0.128 0.315 0.273
3 60 0.67 0.25 1.04 2.79 0.457 0.223 0.682 0.895
4 65 0.67 0.30 1.04 2.33 0.601 0.201 0.903 0.670
5 51 0.19 0.15 3.71 4.75 0.110 0.042 0.592 0.288
6 60 0.39 0,23 1.79 3.00 0.457 0.098 1.179 0.426
7 76 0.59 0.42 1.18 1.67 0.074 0.049 0.127 0.118
8 46 0.20 0.37 3.51 1.89 0.204 0.240 1.034 0.654
9 55 0.26 0.17 2.62 4.20 0.058 0.037 0.218 0.224
10 65 0.48 0.23 1.44 3.04 0.281 0.055 0.586 0.238
Mean 0.48 0.29 1.87 2.79 0.273 0.118 0.614 0.421
SD 0.22 0.11 1.05 1.05 0.181 0.078 0.347 0.246
Control
1 67 0.21 0.20 3.29 3.54 0.085 0.058 0.407 0.298
2 70 0.41 0.36 1.71 1.94 0.129 0.067 0.318 0.188
3 53 0.25 0.24 2.74 2.89 0.181 0.132 0.714 0.548
Mean 0.29 0.27 2.58 2.79 0.132 0.086 0.480 0.345
SD 0.11 0.08 0.80 0.80 0.048 0.040 0.208 0.186
Abbreviations are: A, elimination rate constant; t1,2, elimination half-life; CL, total body clearance; V. apparent volume of distribution.
Table 3. Estrone sulfate (E1S) and equilin sulfate (EQS) plasma levels (jsg/ml) after repeated conjugated estrogen infusions
Time after the first dose hr
24+6 48+6 72+6 96+6
E1S EQS E1S EQS E1S EQS E1S EQS
Patient
1
2
3
4
5
6
7
8
9
10
ND
ND
ND
0.019
0.072
ND
0.099
0.028
0.074
0.035
ND
ND
0.017
0.026
0.158
ND
0.140
0.063
0.168
0.060
ND
ND
ND
ND
NA
ND
0.111
0.172
ND
0.021
ND ND
ND ND
ND ND
ND ND
NA NA
ND ND
0.133 0.075
0.180 0.254
ND ND
0.038 0.035
ND
ND
ND
ND
NA
ND
0.055
0.190
0.101
0.041
ND
ND
0.068
ND
0.098
0.080
ND
ND
ND
0.068
ND
0.175
0.063
ND
Control
1
2
3
0.104
ND
0,025
0.125
ND
ND
0.123
0.022
0.028
0.131 0.120
ND ND
ND 0.022
0.112
ND
ND
0.133
ND
0.025
0.128
ND
ND
Abbreviations are: ND, not detectable (<10 ng/ml); NA, not available.
their metabolites, which is matter of few hours, and the effect
on bleeding time which, after repeated administrations, lasts for
14 days or more. The interpretation of this finding lies on the
proposed models of estrogen action [19, 20] which suggest that
estrogens enter the cell and bind with high affinity receptor
proteins on the cytosol. The binding of estrogens to estrogen-
responsive cells induces a change in the receptor which pro-
motes the translocation of the complex into the nucleus and its
retention in the chromatin. The time necessary for the initiation
of estrogen response and the duration of the response can well
be related to the retention of the estrogen-receptor complex in
the nucleus. Apparently platelets do not have specific binding
sites for estrogens [21]; at variance, endothelial cells have been
found to possess estrogen receptors [221. Whether the long
lasting effect of estrogens on bleeding time in our experimental
condition is mediated via endothelial cell receptors remains to
be investigated.
In summary our results show that: a) single infusion of
conjugated estrogen at a dose of 0.6 mg/kg consistently and
significantly shortens bleeding time; the effect is detectable
within six hours of the beginning of the infusion, but is short
lasting; b) four or five consecutive infusions of conjugated
estrogens (cumulative dose ranging from 98 to 228 mg) are
necessary to induce a long lasting and more pronounced short-
ening of bleeding time in uremics; c) the effect of conjugated
estrogens on bleeding time in uremics is always reversible, and
after 25 days all patients had a bleeding time value comparable
to the basal one; d) the pharmacokinetics of conjugated estro-
gens in uremics is comparable to that of normal subjects. In
particular, no accumulation of E1S and its metabolites is
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detectable in the blood following repeated administrations to
uremics.
Further studies are necessary to elucidate estrogens' mech-
anism of action in shortening bleeding time in chronic renal
failure patients.
Acknowledgments
This study was supported by funds from the National Institutes of
Health (U.S.) grant no. HL 37491-02. We are grateful to Professor
Ennio C. Rossi for fruitful discussion and criticism. We are also
indebted to Doctors Giuliano Mecca and Giulio Mingardi for allowing
us to study their patients. Cristina Signorelli helped prepare the
manuscript.
Reprint requests to Dr. Giuseppe Remuzzi, Mario Negri Institute for
Pharmacological Research, Via Gavazzeni, 11, 24100 Bergamo, Italy.
References
I. Livio M, MARCHES! D, REMUZZI G, Goi-n E, MECCA G, DE
GAETANO 0: Uraemic bleeding: Role of anaemia and beneficial
effect of red cell transfusions. Lancet 2:1013—1015, 1982
2. FERNANDEZ F, GOUDABLE C, Sir P, TON-THAT H, DURAND D,
SUC JM, BONEU B: Low haematocrit and prolonged bleeding time
in uraemjc patients: Effect of red cell transfusions. Br .1 Haematol
59:139—148, 1985
3. JANSON PA, JUBELIRER SJ, WEINSTEIN M, DEYKIN D: Treatment
of the bleeding tendency in uremia with cryoprecipitate. N Engi J
Med 303:1318—1322, 1980
4. MANNUCCI PM, REMUZZI G, PUSINERI F, LOMBARD! R, VALSEC-
cm C, MECCA 0, ZIMMERMAN TS: Deamino-8-D-arginine vaso-
pressin shortens the bleeding time in uremia. N Eng! J Med 308:8.-
12, 1983
5. WATSON AJS, KEOGH JAB: Effect of l-deamino-8-D-arginine vaso-
pressin on the prolonged bleeding time in chronic renal failure.
Nephron 32:49—52, 1982
6. SHAPIRO MD, KELLEHER SP: Intranasal deamino-8-D-argininc
vasopressin shortens the bleeding time in uremia. Am J Nephro! 4:
260—261, 1984
7. Liu YK, KOSFELD RE, MARCUM SG: Treatment of uraemic
bleeding with conjugated oestrogen. Lancet 2:887—890. 1984
8. Livio M, MANNUCCI PM, VIGANO' G, MINGARDI G, LOMBARD! R,
MECCA G, REMUZZI G: Conjugated estrogens for the management
of bleeding associated with renal failure. N Eng! J Med 315:731—
735, 1986
9. Oestrogens and progestins in relation to human cancer. IARC
Monogr Eva! Carcinog Risk Chem Hum 21:83—129, 1979
10. SHAPIRO S. KELLY JP, ROSENBERG L, KAUFMAN DW, HELMRICH
SP, ROSENSHEIN NB, LEWIS JL, KNAPP RC, STOLLEY PD, SCHOT-
TENFELD D: Risk of localized and widespread endometrial cancer
in relation to recent and discontinued use of conjugated estrogens.
N Engi J Med 313:969—972, 1985
11, GIBALDI M, PEIUUER B: Pharmacokinetics. New York, Marcel
Dekker Inc., 1975
12. FRIEDMAN M: The use of ranks to avoid the assumption of
normality implicit in the analysis of variance. JAm Stat Assoc 32:
675—701, 1937
13. LINTON M, GALLO PS: The Practical Statistician: Simpl4fied Hand-
book of Statistics. Monterey, Brooks/Cole Publishing Company,
1975
14. STEINER RW, COGGINS C, CARVALHO ACA: Bleeding time in
uremia: A useful test to assess clinical bleeding. Am J Hematol 7:
107—1 17, 1979
15. REMUZZI G: Bleeding in renal failure. Lancet 1:1205—1208, 1988
16. RUDER HJ, LORIAux L, LIPsErr MB: Estrone sulfate: Production
rate and metabolism in man. J Clin Invest 51:1020-1033, 1972
17. LONGCOPE C: The metabolism of estrone sulfate in normal males. J
Clin Endocr 34:113—122, 1972
18. MUELLER G, GORSKI J, AIZAWA Y: The role of protein synthesis in
early estrogen action. Proc Nat! Acad Sci USA 47:16.4—167, 1961
19. JENSEN EV, MOHLA S. GORELL T, TANAKA S, DESOMBRE ER:
Estrophile to nucleophile in two easy steps. .1 Steroid Biochem 3:
445—458, 1972
20. O'MALLEY BW, MEANS AR: Female steroid hormones and target
cell nuclei. Science 183:610—620, 1974
21. CHANG W-C, NAKAO J, ORIMO H, TA! H-H, MUROTA S-I: Stimu-
lation of 12-lipoxygenase activity in rat platelets by 17/3-estradiol.
Biochem Pharmacol 3 1:2633-2638, 1982
22. COLBURN P, BuONAssIsI V: Estrogen-binding sites in endothelial
cell cultures. Science 201:817—819, 1978
